In vivo therapeutic effect of IMC-EB10 in BaF3-ITD leukemia model. Athymic nude mice (10 per group) with BaF3-ITD leukemia were treated intraperitoneally with indicated doses of antibodies 3 times weekly. Mouse survival was monitored daily. Compared with control IgG, treatment with IMC-EB10 (500 μg and 100 μg) significantly prolonged survival of the mice.